Valeo Pharma, Inc. engages in the acquisition and in-licensing of branded pharmaceutical and hospital specialty products for sale. The company is headquartered in Kirkland, Quebec and currently employs 70 full-time employees. The firm acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The firm is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The firm's wholly owned subsidiary is VPI Pharmaceuticals Inc.
Follow-Up Questions
Valeo Pharma Inc 'in CEO'su kimdir?
Mr. Al Moghaddam 2024 'den beri şirketle birlikte olan Valeo Pharma Inc 'in Chief Executive Officer 'ıdır.
VPHIF hissesinin fiyat performansı nasıl?
VPHIF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Valeo Pharma Inc için ana iş temaları veya sektörler nelerdir?
Valeo Pharma Inc Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Valeo Pharma Inc 'in piyasa değerlemesi nedir?
Valeo Pharma Inc 'in mevcut piyasa değerlemesi $0 'dir
Valeo Pharma Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 5 analist Valeo Pharma Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 1 güçlü al, 3 al, 1 tut, 0 sat ve 1 güçlü sat içermektedir
